Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary CD122 antagonist targeting autoimmune and autoimmune-related conditions. The company aims to reduce the activity of natural killer cells and specific T cell subsets, with ongoing studies in celiac disease demonstrating a favorable safety profile.
Funding
Funding not disclosed
Founders
Product
Problem
Autoimmune and autoimmune-related conditions involve dysregulation of the immune system, leading to chronic inflammation and tissue damage. Current treatments often have broad immunosuppressive effects, resulting in significant side effects and incomplete disease control. There is a need for more targeted therapies that can selectively modulate specific immune pathways involved in these diseases.
Solution
Forte Biosciences is developing FB102, a CD122 antagonist, as a targeted therapeutic for autoimmune and autoimmune-related conditions. FB102 aims to reduce the activity of natural killer (NK) cells and specific T cell subsets, which play a key role in the pathogenesis of these diseases. By selectively targeting CD122, a subunit of the IL-2/IL-15 receptors, FB102 modulates key regulatory pathways involved in immune responses. Clinical studies in celiac disease have demonstrated a favorable safety profile, suggesting potential for broader application in other autoimmune disorders.
Target Audience
The primary target audience includes individuals suffering from autoimmune and autoimmune-related conditions, as well as physicians specializing in rheumatology, gastroenterology, and other related fields.
Features
- Proprietary CD122 antagonist molecule
- Selective modulation of NK cells and specific T cell subsets
- Targets IL-2/IL-15 receptor signaling pathways
- Demonstrated reduction in NK cell pharmacodynamic marker
- Completed Phase 1 healthy volunteer study showing good safety profile
- Ongoing patient-based studies in celiac disease